肿瘤细胞治疗研究
英文原题：Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
多发性骨髓瘤（MM）是一种浆细胞恶性肿瘤，全球受累患者数量不断增加。
多发性骨髓瘤（MM）是一种浆细胞恶性肿瘤，全球患者人数不断增加。尽管人们努力理解其发病机制并开发新疗法，MM 仍无法治愈。CAR T 细胞疗法（CAR）和双特异性 T 细胞衔接器（BiTE）等新型免疫疗法正密集靶向不同表面抗原，包括 BMCA、SLAMF7（CS1）、GPRC5D、FCRH5 或 CD38。然而，对于符合移植条件的患者，干细胞移植仍不可或缺。研究提示，提早使用免疫疗法可能显著改善结局。本文总结目前有关 MM 中 CAR 和 BiTE 的临床文献，并比较这两种 T 细胞免疫疗法，讨论有望推动新临床试验开展的潜在治疗策略，包括将 T 细胞免疫疗法作为移植桥接治疗。
Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remains an incurable disease. Novel immunotherapies, such as CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE), are intensively targeting different surface antigens, such as BMCA, SLAMF7 (CS1), GPRC5D, FCRH5 or CD38. However, stem cell transplantation is still indispensable in transplant-eligible patients. Studies suggest that the early use of immunotherapy may improve outcomes significantly. In this review, we summarize the currently available clinical literature on CAR and BiTE in MM. Furthermore, we will compare these two T cell-based immunotherapies and discuss potential therapeutic approaches to promote development of new clinical trials, using T cell-based immunotherapies, even as bridging therapies to a transplant.
MEMBER ACCOUNT
登录成功会直接打开下一页。
